|
|
Vaccine Detail
|
Poliovirus T-Helper Epitope (PV103-115)-keto-Echinocystic Acid (kEA) Saponin–MUC1 Tricomponent Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Poliovirus T-Helper Epitope (PV103-115)-keto-Echinocystic Acid (kEA) Saponin–MUC1 Tricomponent Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: 16-met MUC1 (GVTSAPDTRPAPGSTA) (Fuentes et al., 2026)
- Immunization Route: subcutaneous injection
- Description: A fully synthetic, self-adjuvanting tricomponent vaccine construct (10 PV–kEA–MUC1) built on a streamlined echinocystic acid-derived minimal saponin scaffold (kEA) covalently linked via an amide bond to an unglycosylated MUC1 VNTR peptide (GVTSAPDTRPAPGSTA), with the CD4+ T-helper epitope from poliovirus (PV103-115: KLFAVWKITYKDT) incorporated at the triterpene C3-ketone position via oxime ligation. A corresponding Tn-glycosylated comparator construct (9 PV–kEA–TnMUC1; GVTSAPDT(α-GalNAc)RPAPGSTA) was evaluated in parallel. No external adjuvant or protein carrier was used; self-adjuvanting activity was provided by the saponin-based construct. Administered subcutaneously in PBS to C57BL/6 mice (3 injections; days 0, 11, and 21; 0.40 mM). PV–kEA–MUC1 induced significantly increased IgM and IgG responses relative to dicomponent kEA–MUC1, with IgG levels not significantly different from the PV–QA–MUC1 positive control (S3); induced IgG cross-reacted with TnMUC1 antigen. PV–kEA–TnMUC1 generated lower overall responses, although IgM levels exceeded those induced by kEA–TnMUC1 and PV–kEA–Tn. Antisera from both tricomponent constructs selectively bound native MUC1 on MCF-7 breast cancer cells by confocal microscopy and flow cytometry (fluorescence intensity: 9 < 10 < S3), whereas no binding was observed to HEK293T cells or with antisera from dicomponent constructs (7, 8). No mouse weight loss or adverse events were observed following immunization; in contrast, the PV–QA–MUC1 positive control caused approximately 4% weight loss on day 1 (Fuentes et al., 2026).
|
| Host Response |
|
|
| References |
|
|
|
